Cross-sectional study examines cancer medicine approvals for adult solid tumors, indicating evolving therapeutic landscape.
This cross-sectional study examines trends in cancer medicine approvals by the US Food and Drug Administration (FDA) for adult solid tumors between 2006 and 2025, including both original and supplemental indication approvals.
No takes yet. Share an insight, caveat, or question.
Shkabari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: